Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus chemoradiotherapy in muscle-invasive bladder cancer not undergoing cystectomy
2018-003447-34Phase 2Completed
- Sponsor
- Hellenic Genito-Urinary Cancer Group
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of nivolumab in muscle-invasive bladder carcinoma (MIBC) (2 arms), sponsored by Hellenic Genito-Urinary Cancer Group. Primary endpoint: Locoregional control rate at 2 years. Started Feb 2019; status: completed.
02
Drugs
03
Conditions
muscle-invasive bladder carcinoma (MIBC)
Beyond the preview
Go deeper on 2018-003447-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003447-34.